SEC Form 4 · accession 0001209191-19-002065
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 3, 2019 | S | 3,278 | $12.36 | D | 66,810 | D | |
| Common Stock | holding | — | — | — | 314,066 | I | By the Michael D.Clayman 2006 Revocable Trust | |
| Common Stock | holding | — | — | — | 24,600 | I | By the Michael D. Clayman Irrevocable Trust | |
| Common StockF3 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2018.
- F2Includes 922 shares of Common Stock that were acquired by the Reporting Person on December 20, 2018 at $10.48 per share pursuant to the Issuer's Employee Stock Purchase Plan.
- F3Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.